3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Dermatologic
2
Conditions
Neoplasms
2
Mycosis Fungoides
2
Lymphoproliferative Disorders
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, T-Cell
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Lymphatic Diseases
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Interventions
Rituximab
66
Cyclophosphamide
52
fludarabine phosphate
26
fludarabine
22
Filgrastim
21
Vincristine
19
Methotrexate
19
Melphalan
19
Doxorubicin
18
Radiotherapy
17
Etoposide
17
Prednisone
16
Tacrolimus
15
Whole-Body Irradiation
14
Mycophenolic Acid
14
Cytarabine
14
Peripheral Blood Stem Cell Transplantation
13
Gemcitabine
13
Cyclosporine
13
Antilymphocyte Serum
13
Lenalidomide
12
Busulfan
11
Bortezomib
11
Granulocyte Colony-Stimulating Factor
9
Alemtuzumab
9
sargramostim
8
Dexamethasone
8
Cord Blood Stem Cell Transplantation
8
pembrolizumab
7
ibritumomab tiuxetan
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Lymphoma
×
cobomarsen
×
Clear all
NCT03713320
2022-04-08
SOLAR
miRagen Therapeutics, Inc.
Phase 2
Terminated
37 enrolled
23 charts
NCT03837457
2020-11-19
PRISM
miRagen Therapeutics, Inc.
Phase 2
Terminated
8 enrolled